A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors

NCT06427057 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Urinary System Tumor

Interventions

DRUG: Cadonilimab plus chemotherapy
DRUG: Cadonilimab plus TKI

Sponsor

Tongji Hospital